市場調查報告書
商品編碼
1276796
角膜植入物全球市場規模、份額和行業趨勢分析報告:按疾病類型、手術類型、最終用戶、地區展望和預測,2023-2029 年Global Corneal Implants Market Size, Share & Industry Trends Analysis Report By Disease Type, By Procedure Type (Penetrating Keratoplasty, Endothelial Keratoplasty, and Others), By End User, By Regional Outlook and Forecast, 2023 - 2029 |
到 2029 年,角膜植入物的市場規模預計將達到 5.951 億美元,預測期內復合年增長率為 6.4%。
眼睛的角膜執行幾個重要的功能,例如保護眼睛的內部組織、輔助屈光力以及將光線以最小的散射和光學退化聚焦到視網膜上。需要角膜移植的疾病包括福赫氏營養不良、圓錐角膜、角膜炎、角膜潰瘍、角膜瘢痕和角膜水腫,根據疾病的嚴重程度,可能需要進行角膜移植。
隨著角膜問題的頻繁發生,角膜植入物的市場正在擴大。新興市場角膜失明率的增加和對角膜移植的需求也促進了市場擴張。角膜植入物市場的擴張預計將受到醫療保健支出和基礎設施的增加、政府在醫療保健領域政策的轉變、可支配收入的增加以及製藥行業的發展的推動。
COVID-19 的影響分析
COVID-19 大流行破壞了角膜植入物市場。為了節省成本和降低感染風險,許多醫院和診所不得不推遲或取消角膜移植等非緊急手術,導致角膜植入物市場遭遇重大挫折。特別是在大流行的早期階段,地方和國家當局嚴格的封鎖規定限制了患者就診以獲得非必要護理。角膜移植術和視力恢復手術等眼科手術被歸類為可以推遲的擇期手術,進一步削弱了市場表現。
市場增長因素
角膜失明和其他視力損害疾病的病例增加
據估計,全世界有 1000 萬人被診斷出患有雙側角膜失明,這使得角膜疾病成為導致失明的主要原因之一。角膜混濁佔所有病例的 3.2%,使其成為全球最常見的失明原因之一。根據世界衛生組織 (WHO) 的一份新報告,包括 200 萬沙眼患者在內的 600 萬人患有角膜相關性失明或中度至重度視力障礙。近視或遠視影響全球約 22 億人。其中至少有 10 億(約一半)是可預防的視力喪失病例,但尚未得到解決。
對人工角膜的需求不斷增長
人工角膜可以克服眼表疾病、免疫排斥和免疫移植的風險。人造角膜不易膨脹,從而減少了光散射和積水。由於角膜失明的高發率和角膜供體的缺乏,預計角膜植入物製造商將有較大的增長速度。此外,由於角膜感染患病率的增加,預計人工角膜植入物將出現顯著增長。因此,與傳統角膜相比具有各種優勢的人造角膜的出現有望促進角膜植入物市場的增長。這將推動市場增長。
市場製約因素
阻礙角膜植入物傳播的問題
發展中國家的大多數醫療機構將角膜植入物視為門診手術。因此,角膜植入物在這些地區並不是很受歡迎。在這些地區,如果沒有足夠的醫療基礎設施,現有企業和新企業很難進入市場。近年來,隨著有希望的替代方法的出現,角膜內環段移植的接受率持續下降。因此,建立角膜移植手術中心所需的高資金成本、供體短缺等預計將阻礙市場增長。
治療類型的前景
根據手術類型,角膜植入物市場分為滲透性角膜移植術、內皮角膜移植術等。到 2022 年,內皮角膜移植術部分在角膜植入物市場中佔據了重要的收入份額。這是因為最現代類型的角膜移植使用內皮角膜移植術,它僅替換受損組織,而不是角膜的整個厚度。由於感染機會和眼睛表面損傷較少等特點,該程序有助於更快更好地恢復視力。
病種展望
角膜植入物市場按疾病類型分為圓錐角膜、Fuch 營養不良、感染性角膜炎等。Fuchth 的營養不良部分代表了 2022 年角膜植入物市場的最大收入份額。這是由於人們對眼睛健康的瞭解越來越多,而 Fuchs 營養不良症越來越普遍。在 Fuchs 營養不良患者中,眼睛前部的透明層(角膜)變得充滿液體,導致角膜腫脹和變厚。這會導致眩光、起霧或視力障礙,以及眼睛不適。
最終用戶視角
按最終用戶劃分,角膜植入物市場分為醫院、眼科中心等。2022 年,醫院部門在角膜植入物市場的收入份額最高。這是由於高素質的醫療保健專業人員的可用性以及私人和團體保險計劃中以醫院為基礎的醫療保健服務的覆蓋範圍不斷擴大。醫院也有專門的設備和設施,例如手術室、重症監護室和專科眼科手術室。因此,由於專家和高科技設備的存在來進行這些手術,預計在預測期間醫院部門的增長將會增加。
區域展望
按地區劃分,對北美、歐洲、亞太地區和 LAMEA 的角膜植入物市場進行了分析。北美地區將在 2022 年以最大的收入份額引領角膜植入物市場。在這種背景下,由於醫療保健基礎設施的發展,角膜疾病的患病率有所增加。此外,人工角膜植入物的重要生產商數量激增以及公眾對健康和福祉的認識不斷提高,也有助於該地區的市場增長。此外,圓錐角膜的流行也有望增加角膜植入物的需求,這有望刺激北美市場的擴張。
The Global Corneal Implants Market size is expected to reach $595.1 Million by 2029, rising at a market growth of 6.4% CAGR during the forecast period.
Sometimes referred to as corneal inlays, corneal implants are optical devices placed into the cornea to improve eyesight. In addition to treating hyperopia, myopia, and astigmatism, the corneal implant technique is performed in cases of keratoconus and other degenerative disorders. Corneal implants are mostly used to treat presbyopia in adults by enhancing close vision and lowering the need for glasses.
A corneal transplant replaces the cornea with a donor or synthetic cornea. In this surgery, artificial or donor corneas are used to replace the cornea. The donor corneas used for transplantation are stored at eye banks in a storage medium. A synthetic cornea can also be chosen by transplant patients who can't accept a human donor cornea.
The cornea in the eye serves several crucial functions, including safeguarding interior eye tissues, assisting with refractive power, and focusing light on the retina with minimal possible scatter and optical degradation. Depending on their severity, certain disorders require corneal transplantation, including Fuchs dystrophy, keratoconus, keratitis, corneal ulcers, corneal scarring, and corneal edema.
The market for corneal implants is expanding as corneal problems are becoming more common. Also, the rise in corneal blindness in developing nations and the demand for corneal transplants contribute to the market's expansion. The expansion of the corneal implant market is anticipated to be fueled by an increase in healthcare spending and infrastructure, a shift in government policy in the healthcare sector, an increase in disposable income, and the development of the pharmaceutical industry.
COVID-19 Impact Analysis
The COVID-19 pandemic had a damaging effect on the Corneal Implant market. To save cost and lower the danger of infection, many hospitals and clinics had to postpone or cancel non-urgent procedures, such as corneal transplants, which caused a significant setback for the corneal implants market. Particularly during the early stages of the pandemic, patients' hospital trips for non-essential treatments were restricted by the severe lockdown regulations imposed by the local and national authorities. The classification of ophthalmic procedures, such as keratoplasty and sight-restoring surgeries, as elective surgical procedures that can be postponed further hindered the market's financial performance.
Market Growth Factors
Rising cases of corneal blindness and other vision impairment diseases
With an estimated 10 million patients diagnosed with bilateral corneal blindness globally, corneal disorders are one of the leading causes of blindness. At 3.2% of all cases, corneal opacity ranks amongst the world's most common causes of blindness. Six million people, including 2 million with trachoma, have cornea-related blindness or moderate to severe visual impairment, according to a new World Health Organization (WHO) report. Near- or distance vision impairment impacts approximately 2.2 billion people globally. At least 1 billion of these cases, roughly half involved vision impairment that could have been prevented or was not addressed.
The surging requirement for artificial cornea
The artificial cornea can overcome ocular surface disease, immunological rejection, and immune graft danger. The artificial cornea has reduced swellability, which means it will have less light scattering and water accumulation. A significant rate of growth is anticipated for corneal implant manufacturers due to the high prevalence of corneal blindness and the absence of corneal donors. Furthermore, the artificial cornea implant is anticipated to grow significantly due to the increasing prevalence of corneal infections. Thus, the presence of the artificial cornea with various benefits over the traditional one is expected to surge the corneal implant market growth. This will expedite the market's growth.
Market Restraining Factors
Issues restricting wider adoption of corneal implants
Most healthcare facilities in developing nations treat corneal implants as outpatient procedures. This has made corneal implants less popular in these parts of the world. If there isn't enough healthcare infrastructure in these areas, it would be hard for existing and new businesses to break into the market. Since promising alternatives have become available, the acceptance rate of intrastromal corneal ring segment implantation has been going down over the past few years. Thus, the need for high capital to establish surgery centers for cornea implants, lack of donors, and other factors are expected to hinder the market growth.
Procedure Type Outlook
Based on procedure type, the corneal implants market is segmented into penetrating keratoplasty, endothelial keratoplasty and others. The endothelial keratoplasty segment acquired a substantial revenue share in the corneal implants market in 2022. This is because the most recent kind of corneal transplant uses endothelial keratoplasty, which replaces only the damaged tissue rather than the entire thickness of the cornea. This procedure aids in quicker and better sight recovery due to its features like less possibilities of infection and eye surface injuries.
Disease Type Outlook
On the basis of disease type, the corneal implants market is divided into keratoconus, fuchs' dystrophy, infectious keratitis and others. The fuchs' dystrophy segment witnessed the largest revenue share in the corneal implants market in 2022. This is owing to the increased knowledge of ocular health and Fuchs' dystrophy being more common. The clear layer (cornea) on the front of the eye becomes clogged with fluid when a person has Fuchs' dystrophy, which causes the cornea to enlarge and thicken. As a result, glare, clouded or impaired vision, and eye discomfort may result.
End User Outlook
By end-user, the corneal implants market is classified into hospitals, ophthalmic centers and others. The hospitals segment registered the highest revenue share in the corneal implants market in 2022. This is due to the availability of highly qualified healthcare professionals and the expansion of private & group insurance plans' coverage of hospital-based healthcare services. Hospitals also have specialist equipment and facilities, such as operating rooms, intensive care units, and units for specialty eye surgery. Hence, with the presence of specialists and high-tech machinery to perform these surgeries, the hospital segment growth is expected to boost in the projected period.
Regional Outlook
Region-wise, the corneal implants market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the corneal implants market by generating the maximum revenue share in 2022. This is because of a rise in the infrastructure for healthcare and an increase in the prevalence of corneal illnesses. Also, a surge in the number of significant producers of artificial corneal implants and a rise in public awareness of health and well-being contribute to the market growth in this area. Furthermore, the prevalence of keratoconus is also anticipated to enhance demand for corneal implants, which is anticipated to spur market expansion in North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Presbia PLC, CorNeat Vision Ltd., Alcon, Inc., AJL Opthalmic SA, LinkoCare Life Sciences AB, CorneaGen, DIOPTEX GmbH, Mediphacos Industrias Medicas S.A., EyeYon Medical Ltd., and KeraMed, Inc.
Strategies Deployed in Corneal implants Market
Nov-2022: Alcon took over Aerie Pharmaceuticals, a US-based clinical-stage pharmaceutical company. The addition of Aerie expands Alcon's market presence in the ophthalmic pharmaceutical market. Moreover, Aerie's deep technical expertise supports the company's endeavor to develop a comprehensive portfolio of ophthalmic pharmaceuticals.
Apr-2022: CorneaGen introduced EndoSerter-PL, an FDA-approved insertion device. The single-use graft insertion device is equipped with masterly processed tissue to smoothen the DSEK surgeries.
Jan-2022: Alcon took over Ivantis, a US-based manufacturer of surgical devices for the treatment of eye diseases. The acquisition brings in Ivantis' Hydrus Microstent, which would be added to the acquiring company's global portfolio. Further, the addition of Ivantis reinforces Alcon's global surgical portfolio.
Jan-2022: CorneaGen signed an agreement with MellingMedical, a provider of pharmaceuticals, surgical, wound care, and etc. products. The agreement involves Melling providing Federal Health facilities with CorneaGen tissue. The partnership broadens CorneaGen's devotion to transforming the lives of people with corneal diseases, particularly America's veterans.
Jun-2021: EyeYon Medical for its EndoArt received CE Mark. EndoArt is a synthetic implant, which takes place of human endothelium that a body cannot regenerate. This approval enables the company to work in close relations with the healthcare providers to make patients live a better quality of life.
Mar-2021: CorNeat Vision came into partnership with LiveU and Alcon, a US-based provider of live video streaming services. Alcon is a US-based Ophthalmology company. The partnership focuses on implementing a remote surgeon virtual presence (RSVP) solution. The partnership involves cashing on Alcon's NGENUITY 3D Visualization System to carry out remote training of cornea experts located in Toronto. The partnership further boosts CorNeat's CorNeat KPro sales, as it would allow the company to train physicians across the world without physical presence.
Mar-2019: Alcon completed the acquisition of PowerVision, a US-based developer of implantable intraocular lenses. The acquisition reflects Alcon's devotion to driving forward the growth and innovation in AT-IOLS, advanced technology intraocular lenses.
Feb-2019: CorneaGen took over KeraLink Domestic Eye Bank Operations, a US-based provider of eye bank services. The acquisition broadens the company's surgical product offerings. Further, the addition of KeraLink Domestic Eye Bank Operations also brings in partnerships with industry and research communities which would further enhance the acquiring company's access to major and important discoveries in corneal disease treatment.
Market Segments covered in the Report:
By Disease Type
By Procedure Type
By End User
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures